Sorafenib

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: ===Pharmacokinetics=== {| class="wikitable" border="1" width="40%" style="text-align:center" |- ! colspan="6" align="center"| VEGFR Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Tran...)
Line 3: Line 3:
{| class="wikitable" border="1" width="40%" style="text-align:center"
{| class="wikitable" border="1" width="40%" style="text-align:center"
|-
|-
-
! colspan="6" align="center"| VEGFR Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref><ref>R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)</ref><ref>PMID:16133532</ref><ref>PMID:20821331</ref><ref>PMID:20717111</ref>
+
! colspan="6" align="center"| VEGFR Inhibitor [[Pharmacokinetics]] <ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref><ref>R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)</ref><ref>PMID:16133532</ref><ref>PMID:20821331</ref><ref>PMID:20717111</ref>
|-
|-
! Parameter
! Parameter
Line 9: Line 9:
! [[Sorafenib]] (Nexavar)
! [[Sorafenib]] (Nexavar)
|-
|-
-
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
+
! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
! 8
! 8
! 8.3
! 8.3
|-
|-
-
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
+
! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
! 24.6
! 24.6
! 460
! 460
|-
|-
-
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
+
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
! Variable
! Variable
! 29-49
! 29-49
|-
|-
-
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
+
! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
! 95
! 95
! 99
! 99
|-
|-
-
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
+
! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
! 83
! 83
! 29
! 29
|-
|-
-
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
+
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
! 1921
! 1921
! 11040
! 11040

Revision as of 12:53, 9 December 2010

Pharmacokinetics

VEGFR Inhibitor Pharmacokinetics [1][2][3][4][5]
Parameter Sunitinib (Sutent) Sorafenib (Nexavar)
Tmax (hr) 8 8.3
Cmax (ng/ml) 24.6 460
Bioavailability (%) Variable 29-49
Protein Binding (%) 95 99
T1/2 (hr) 83 29
AUC (ng/ml/hr) 1921 11040
Dosage (mg) 50 50
Metabolism Hepatic (CYP3A4) Hepatic (CYP3A4)

Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky, Joel L. Sussman

Retrieved from "http://52.214.119.220/wiki/index.php/Sorafenib"
Personal tools